CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM 2018 EXECUTIVE SUMMARY.
ABBREVIATIONS A1C hemoglobin A1C; AACE American Association of Clinical Endocrinologists; ACCORD Action to Control Cardiovascular Risk in Diabetes; ACCORD BP Action to Control Cardiovascular Risk in Diabetes Blood Pressure; ACEI angiotensin converting enzyme inhibitor; ADVANCE Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation; AGI alpha glucosidase inhibitor; apo B apolipoprotein B; ASCVD atherosclerotic cardiovascular disease; BAS bile acid sequestrant; BCR QR bromocriptine quick release; BMI body mass index; BP blood pressure; CCB calcium channel blocker; CHD coronary heart disease; CKD chronic kidney disease; CVD cardiovascular disease; DASH Dietary Approaches to Stop Hypertension; DPP4 dipeptidyl peptidase 4; eGFR estimated glomerular filtration rate; ER extended release; FDA Food and Drug Administration; GLP1 glucagon like peptide 1; HDL C high density lipoprotein cholesterol; IMPROVE IT Improved Reduction of Outcomes: Vytorin Efficacy International Trial; LDL C low density lipoprotein cholesterol; LDL P low density lipoprotein particle; Look AHEAD Look Action for Health in Diabetes; NPH neutral protamine Hagedorn; OSA obstructive sleep apnea; RCT randomized controlled trial; SU sulfonylurea; SGLT2 sodium glucose cotransporter 2; SMBG self monitoring of blood glucose; T2D type 2 diabetes; TZD thiazolidinedione; VADT Veterans Affairs Diabetes Trial.
Endocrine practice official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists